Bayer Pays $310M For European Rights To Heart Drug

By Yeji Jesse Lee · March 4, 2024, 7:23 PM EST

German pharmaceutical giant Bayer and public biopharmaceutical company BridgeBio announced Monday that they would form a $310 million partnership centered on the experimental heart drug acoramidis....

To view the full article, register now.